IMM-BCP-01 in Mild to Moderate COVID-19
A Randomized, Double-Blind, Placebo-Controlled, First-in-Human, Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Viral Clearance of Single Ascending Doses of IMM-BCP-01 Administered Intravenously in Adults With Mild to Moderate COVID-19
Sponsor: Immunome, Inc.
Terminated
Business decision to discontinue the study based on strategic prioritization.
Listed as NCT05429021, this PHASE1 trial focuses on COVID-19 and SARS-CoV2 Infection and remains terminated or withdrawn. Sponsored by Immunome, Inc., it has been updated 5 times since 2022, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
5 versions recorded-
Oct 2024 — Present [monthly]
Terminated PHASE1
Status: Unknown → Terminated
-
Sep 2024 — Oct 2024 [monthly]
Unknown PHASE1
Status: Recruiting → Unknown
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1
First recorded
Jun 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Immunome, Inc.
- United States Department of Defense
For direct contact, visit the study record on ClinicalTrials.gov .